Versartis Inc (NASDAQ:VSAR) has been given an average rating of “Hold” by the twelve ratings firms that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and two have issued a buy recommendation on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $5.63.
VSAR has been the topic of several recent analyst reports. Cantor Fitzgerald set a $14.00 target price on shares of Versartis and gave the stock a “buy” rating in a report on Friday, October 27th. Zacks Investment Research cut shares of Versartis from a “hold” rating to a “sell” rating in a report on Sunday, January 21st.
In other Versartis news, Director Srinivas Akkaraju purchased 513,872 shares of the company’s stock in a transaction that occurred on Monday, December 4th. The stock was bought at an average price of $2.21 per share, with a total value of $1,135,657.12. Following the completion of the purchase, the director now directly owns 14,955 shares of the company’s stock, valued at approximately $33,050.55. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Company insiders own 10.90% of the company’s stock.
Versartis (NASDAQ:VSAR) opened at $1.98 on Friday. The company has a quick ratio of 1.52, a current ratio of 1.52 and a debt-to-equity ratio of 0.11. Versartis has a fifty-two week low of $1.60 and a fifty-two week high of $24.00. The stock has a market cap of $70.72, a P/E ratio of -0.51 and a beta of 2.35.
Versartis (NASDAQ:VSAR) last issued its earnings results on Thursday, October 26th. The biopharmaceutical company reported ($1.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by ($0.78). During the same period in the previous year, the company posted ($0.92) EPS. research analysts forecast that Versartis will post -4.16 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: This piece was first reported by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/02/02/versartis-inc-vsar-given-consensus-rating-of-hold-by-analysts.html.
Versartis, Inc is an endocrine-focused biopharmaceutical company. The Company is engaged in developing a long-acting form of recombinant human growth hormone, somavaratan (VRS-317), for growth hormone deficiency (GHD), an orphan disease. The Company’s first indication for somavaratan is pediatric GHD.
Receive News & Ratings for Versartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Versartis and related companies with MarketBeat.com's FREE daily email newsletter.